Celltrion Healthcare - Management of rheumatic diseases during the COVID-19 pandemic


Industry room 6
English
Satellite Symposia
03 June 2021 08:15 - 09:45

Learning Objectives:

  • To explore the benefits of subcutaneous formulations of TNF-α inhibitors to manage patients with rheumatic diseases during the COVID-19 pandemic by overviewing recommendations from various medical societies and clinical evidence.
  • To review the recent evidence on the benefits of switching from IV to SC infliximab by addressing various clinical data from pivotal study to meta-analysis as well as recent real-world cases, especially during the COVID-19 pandemic.
  • To understand the clinical program of CT-P17 to demonstrate biosimilarity to reference adalimumab and explore the phase III clinical data of CT-P17 in patients with RA.

Chair(s) of the session

Prof. Dr. Bernard Combe, France

Presentations

Title Time Calendar .ics
Introduction
03 June 2021 08:15 - 08:25 .ics
Clinical practice with TNF-α inhibitors in the era of COVID-19
03 June 2021 08:25 - 08:50 .ics
Benefits of switching from IV to SC infliximab
03 June 2021 08:50 - 09:20 .ics
Clinical data of CT-P17, adalimumab biosimilar
03 June 2021 09:20 - 09:40 .ics
Closing remarks
03 June 2021 09:40 - 09:45 .ics